Novavax shares rise after FDA authorization and guidance upgrade
Novavax shares are trading higher Tuesday after U.S. FDA emergency use authorization for its updated 2026-2027 Nuvaxovid vaccine and an earlier Q2 update that raised full-year revenue guidance.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.